During the week of August 12 – 16, the Patent Trial and Appeal Board (PTAB), issued 26 institution-phase decisions in inter partes review (IPR) proceedings. Nine IPR petitions were denied institution while 17 were instituted; nine of the instituted IPRs were joined to other proceedings that are already ongoing at the agency. Pfizer saw a lot of success last week in having seven IPRs instituted against Sanofi-Aventis, challenging four injectable insulin treatment patents that are at the center of district court infringement litigation between the two parties. The PTAB also instituted IPRs on a series of three LifeNet patents covering tissue graft technologies, which have been asserted against RTI Surgical, including one patent which helped LifeNet earn a multimillion-dollar award for patent infringement in district court.
PTAB Institutes Series of IPRs Brought by Pfizer Against Sanofi Patents
No Comments
Litigation
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- NetSoc Appeals to SCOTUS, Claiming Improper Analysis of Social Network Patent Nixed Under 101
- The View from the Court’s 2 Live Crew: Examining the Thomas/Alito Dissent in Google v. Oracle
- Tillis, Michel and Iancu Back Ericsson in Heated International FRAND Dispute with Samsung
Recent Posts
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- Kappos at PTAB Masters Day 2: PTAB Problems Arose When It Failed to Evolve
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- Countries Like the Philippines are Unable to Utilize IP Flexibilities to Fight COVID-19
- Why the Patent Classification System Needs an Update